44 terminated. 44 Phase 1, 17 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 44 | Terminated 44 |
| Phase 2 | 17 | Terminated 17 |
Follow Revlimid: new trials by email Literature Review of Revlimid trials Research Report on Revlimid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma Belantamab Mafodotin, Daratumumab, Dexamethasone - Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma | Phase 1 | Terminated | Mayo Clinic | 5 | 2021-06-03 | 2025-05-18 |
| Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study Lenalidomide - Demyelinating Sensorimotor Neuropathy | Phase 1 | Terminated | Ohio State University | 11 | 2018-09-10 | 2024-09-27 |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib - Plasmacytoma, Recurrent Multiple Myeloma | Phase 1 | Terminated | National Cancer Institute (NCI) | 35 | 2018-06-14 | 2026-02-10 |
| Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL Venetoclax, Umbralisib, Ublituximab - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | TG Therapeutics, Inc. | 78 | 2018-03-27 | 2022-08-22 |
| Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Lenalidomide, Pembrolizumab - Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Fox Chase Cancer Center | 3 | 2017-03-29 | 2021-12-30 |
| Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant Dexamethasone, Ibrutinib, Laboratory Biomarker Analysis - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Terminated | Mayo Clinic | 18 | 2017-03-10 | 2025-08-17 |
| Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma Ixazomib, Lenalidomide, Rituximab - B Cell Lymphoma, Lymphoma | Phase 1 / Phase 2 | Terminated | Brian Hill | 19 | 2017-02-20 | 2022-09-26 |
| Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma Pembrolizumab, Lenalidomide - Relapsed Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | NYU Langone Health | 6 | 2016-08-29 | 2020-08-14 |
| Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Lenalidomide, Vorinostat, Gemcitabine - Lymphoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2016-06-22 | 2019-12-13 |
| Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease Lenalidomide - Leukemia, Myeloid, Myelodysplastic Syndromes | Phase 1 | Terminated | University of Florida | 11 | 2016-05-16 | 2020-01-27 |
| Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer Lenalidomide - Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Jun Zhang | 7 | 2014-06-01 | 2018-01-18 |
| Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Lenalidomide, Ibrutinib, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Terminated | Georgetown University | 5 | 2014-04-01 | 2018-01-12 |
| Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma lenalidomide, pidilizumab, pharmacological study - Multiple Myeloma | Phase 1 | Terminated | Ohio State University Comprehensive Cancer Center | 20 | 2014-03-03 | 2023-01-27 |
| Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma Lenalidomide, nab-paclitaxel - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | NYU Langone Health | 3 | 2014-03-01 | 2018-10-15 |
| Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma Palbociclib, Dexamethasone, Lenalidomide - Multiple Myeloma | Phase 1 | Terminated | Weill Medical College of Cornell University | 9 | 2014-02-01 | 2018-08-22 |
| Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia lenalidomide, mitoxantrone hydrochloride, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Terminated | Stanford University | 17 | 2014-02-01 | 2018-10-29 |
| Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma Lenalidomide, Dexamethasone, All-Trans Retinoic Acid (ATRA) - Myeloma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 2 | 2013-12-01 | 2016-09-14 |
| Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Laboratory Biomarker Analysis, Lenalidomide - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission | Phase 1 / Phase 2 | Terminated | Albert Einstein College of Medicine | 3 | 2013-12-01 | 2020-05-14 |
| Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma Oprozomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Amgen | 22 | 2013-10-28 | 2022-11-14 |
Showing 20 of 44. Sign in to see all of them.
Multiple Myeloma (12) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Lymphoma (8) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Mantle-Cell (5) · Lymphoma, Non-Hodgkin (5) · Recurrence (5) · Myelodysplastic Syndromes (4) · Burkitt Lymphoma (3) · Leukemia, Myeloid, Acute (3) · Lymphoma, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Waldenstrom Macroglobulinemia (3) · Carcinoma, Non-Small-Cell Lung (2) · Hodgkin Disease (2)
M.D. Anderson Cancer Center (6) · Case Comprehensive Cancer Center (3) · Mayo Clinic (2) · NYU Langone Health (2) · TG Therapeutics, Inc. (2) · Albert Einstein College of Medicine (1) · Amgen (1) · Baylor College of Medicine (1) · Beth Israel Deaconess Medical Center (1) · Brian Hill (1) · Celgene (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Fox Chase Cancer Center (1)
United States (41) · Germany (2) · Italy (1) · Japan (1) · South Korea (1) · Switzerland (1)
Amitabha Mazumder, MD (1) · Bakri Elsheikh, MBBS (1) · Brian Hill, MD, PhD (1) · Catherine Diefenbach, MD (1) · Chaitra Ujjani, MD (1) · David Iberri (1) · Debora Barton, MD (1) · Emmanuel Besa, MD (1) · Felicitas Hitz, MD (1) · Hans C Lee (1) · Hien K Liu, MD (1) · Hun J. Lee, MD (1) · Ira Braunschweig (1) · James K Schwarz, MD (1)
PMID 24914044, PMID 25052451, PMID 29610115, PMID 30190454, PMID 37871300, PMID 38015467
2009 (1), P30CA013330 (1), P30CA036727 (1), P30CA043703 (1), P30CA124435 (1), UM1CA186688 (1)